Human Papillomavirus (HPV)

NIT-02 is a combination of BVAC-C (antigen presenting cells; T cell generator) and Hyleukin (hyFc-fused IL-7; T cell booster) that is the best treatment to treat HPV- derived cancers, mainly cervical cancer and head & neck cancer in which these cancers are derived from HPV 16/18 type infection. BVAC-C generates strong and broad tumor-specific T cells whereas Hyleukin enhances functionality of T cells generated by BVAC-C to express strong anti-tumor effect.

Source:
http://www.cancerresearchuk.org
http://www.cdc.gov/std/hpv/stdfact-hpvandoralcancer.htm
http://www.mountsinai.org





The indication of NIT-03 is HPV Persistent Infection which currently has no Standard of Care. NIT’s proprietary product, Hyleukin, enhances the expansion and function of T cells in chronic infection, and has efficient mucosal delivery by FcRn-dependent mechanism in animal experiments.






Source:
THE PRN NOTEBOOK vol.13 www.prn.org, Sep. 2008; BMC Infectious Diseases 2009, 9:119
Summary Report Update on Human Papilloma Virus and Related Cancers, WHO/ICO HPV information Centre, 2010
JNCI J Natl Cancer Inst-2008-Rodr-uez-513

To install the latest Internet Explorer